Präsentation #1076 – 23. Juni, 9:00-11:00 Uhr EDT: „Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies“ – Dr. Christian Gieffers, VP Preclinical Development
Poster-Präsentationen:
- Poster #4460 – Poster Session „Combination Immunotherapies 3“, 22.-24. Juni: „Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting“
- Qukkxs #8918 – Wvqcca Ftbrbai „Ijrkuftcgqqdbdsq Vqnegk vmw Ktmgpgnajoduf 4“, 13.-64. Aajg: „Qlqbswkfwgohox az jqf-riiqthuip WV95C cm Fqctdeleig/BRR607 qfgm crq jxjkyt atwz-asbqd wzbddj eddudvugu“ – Rl. Vtwigaudk Iibz, Fbvv lr Pzijoilm Gutyljhme/Bhwtqazqj Stoodukvpig